Testing effectiveness (Phase 2)Ended earlyNCT02736448
What this trial is testing
177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors
Who this might be right for
Gastro-entero-pancreatic Neuroendocrine Tumors
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 35